AHR and myeloid sarcoma: The study suggests that tryptamine, through AHR activation, can modulate immune responses and gut microbiota composition, leading to reduced neuroinflammation and amelioration of MS-like symptoms in animal models. This points to the potential of targeting the AHR pathway as a therapeutic strategy in MS